Multiprotein-engineered cells secreting a multispecific antibody
US-2024344030-A1 · Oct 17, 2024 · US
Method for treating or preventing graft versus host disease
US9730960B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9730960-B2 |
| Application number | US-201214124800-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 11, 2012 |
| Priority date | Jun 9, 2011 |
| Publication date | Aug 15, 2017 |
| Grant date | Aug 15, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method of treating or preventing graft versus host disease (GVHD) in a subject receiving a graft comprising hematopoietic cells is provided. The method comprises contacting the graft ex vivo with an amount of a Myxoma Virus effective to inhibit proliferation of T lymphocytes in the graft and to treat or prevent GVHD in the host subject following infusion of the graft into the subject. After the contacting of the graft with the Myxoma Virus, the method comprises transplanting the virus-treated graft into the subject.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating or preventing graft versus host disease (GVHD) in a subject receiving a graft comprising hematopoietic cells, the method comprising: contacting the graft ex vivo with an amount of a Myxoma Virus effective to inhibit proliferation of T lymphocytes in the graft and to treat or prevent GVHD in the subject following transplantation of the graft into the subject; and after the contacting, transplanting the virus-treated graft into the subject, wherein the graft comprises an allogeneic graft. 2. The method of claim 1 , wherein the transplanting comprises a technique from the group consisting of an allogeneic hematopoietic cell transplant, a donor cell infusion, and a supportive blood product transfusion. 3. The method of claim 1 , wherein the graft comprises bone marrow or human peripheral blood cells. 4. The method of claim 1 , wherein the T lymphocytes comprise CD3 + T lymphocytes. 5. The method of claim 1 , further comprising administering at least one of chemotherapy, biotherapy, immunosuppression or radiotherapy to the host subject before transplanting the virus-treated graft into the subject. 6. The method of claim 5 , wherein the graft comprises at least one member from the group consisting of bone marrow and human peripheral blood cells. 7. The method of claim 5 , wherein the subject has a hematologic malignancy.
Assignees
Inventors
Classifications
Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42) · CPC title
Drugs for immunological or allergic disorders · CPC title
Use of virus, viral particle or viral elements as a vector · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9730960B2 cover?
- A method of treating or preventing graft versus host disease (GVHD) in a subject receiving a graft comprising hematopoietic cells is provided. The method comprises contacting the graft ex vivo with an amount of a Myxoma Virus effective to inhibit proliferation of T lymphocytes in the graft and to treat or prevent GVHD in the host subject following infusion of the graft into the subject. After t…
- Who is the assignee on this patent?
- Mcfadden Douglas G, Bartee Eric C, Cogle Christopher R, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K35/28. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).